Terms: = Kidney tumors AND CXCR4, D2S201E, 7852, ENSG00000121966, P61073, NPYY3R, NPY3R, HM89, NPYRL, LESTR, HSY3RR, LCR1, fusin, WHIM, NPYR, FB22, CD184 AND Treatment
26 results:
1. PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating cxcr4/ERK signaling pathway and accelerating glycolysis.
He Y; Wang X; Lu W; Zhang D; Huang L; Luo Y; Xiong L; Li H; Zhang P; Li Q; Liang S
Cell Death Dis; 2022 Feb; 13(2):118. PubMed ID: 35121728
[TBL] [Abstract] [Full Text] [Related]
2. Biokinetics and Dosimetry of
Hänscheid H; Schirbel A; Hartrampf P; Kraus S; Werner RA; Einsele H; Wester HJ; Lassmann M; Kortüm M; Buck AK
J Nucl Med; 2022 May; 63(5):754-760. PubMed ID: 34413147
[TBL] [Abstract] [Full Text] [Related]
3. Silencing of the chemokine CXC receptor 4 (cxcr4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC).
Wang W; Gan Z; Liu Q; Yan S; Mulati R; Wang Y
Bioengineered; 2021 Dec; 12(1):2957-2969. PubMed ID: 34180759
[TBL] [Abstract] [Full Text] [Related]
4. Extramedullary Relapsed Multiple Myeloma treatment With 177Lu-Labeled cxcr4 Endoradiotherapy and Dosimetric Results.
Demirkol MO; Özkan A; Uçar B; Wester HJ; Ferhanoğlu B
Clin Nucl Med; 2021 Aug; 46(8):656-658. PubMed ID: 34034308
[TBL] [Abstract] [Full Text] [Related]
5. The effect of microRNA-330 replacement on inhibition of growth and migration in renal cancer cells.
Liu J; Song X; Ren Z
Biotechnol Appl Biochem; 2022 Apr; 69(2):558-566. PubMed ID: 33605482
[TBL] [Abstract] [Full Text] [Related]
6. A phase 1b trial of the cxcr4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy.
Choueiri TK; Atkins MB; Rose TL; Alter RS; Ju Y; Niland K; Wang Y; Arbeit R; Parasuraman S; Gan L; McDermott DF
Invest New Drugs; 2021 Aug; 39(4):1019-1027. PubMed ID: 33507454
[TBL] [Abstract] [Full Text] [Related]
7. Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.
Murphy DA; Rini BI; Escudier B; Motzer RJ; Wang P; Li S; Williams JA; Tarazi JC; Martini JF
Future Oncol; 2020 Jun; 16(17):1199-1210. PubMed ID: 32363929
[No Abstract] [Full Text] [Related]
8. cxcr4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Saxena R; Wang Y; Mier JW
Melanoma Res; 2020 Feb; 30(1):14-25. PubMed ID: 31524789
[TBL] [Abstract] [Full Text] [Related]
9. Development and Evaluation of an
Brickute D; Braga M; Kaliszczak MA; Barnes C; Lau D; Carroll L; Stevens E; Trousil S; Alam IS; Nguyen QD; Aboagye EO
Mol Pharm; 2019 May; 16(5):2106-2117. PubMed ID: 30883140
[TBL] [Abstract] [Full Text] [Related]
10. The Correlation Between the Immune and Epithelial-Mesenchymal Transition Signatures Suggests Potential Therapeutic Targets and Prognosis Prediction Approaches in kidney Cancer.
Liang J; Liu Z; Zou Z; Tang Y; Zhou C; Yang J; Wei X; Lu Y
Sci Rep; 2018 Apr; 8(1):6570. PubMed ID: 29700419
[TBL] [Abstract] [Full Text] [Related]
11. Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma.
Xiao W; Gao Z; Duan Y; Yuan W; Ke Y
J Exp Clin Cancer Res; 2017 Mar; 36(1):41. PubMed ID: 28279221
[TBL] [Abstract] [Full Text] [Related]
12. Role of Cyclooxygenase-2 Pathway in Creating an Immunosuppressive Microenvironment and in Initiation and Progression of Wilms' Tumor.
Maturu P; Jones D; Ruteshouser EC; Hu Q; Reynolds JM; Hicks J; Putluri N; Ekmekcioglu S; Grimm EA; Dong C; Overwijk WW
Neoplasia; 2017 Mar; 19(3):237-249. PubMed ID: 28254151
[TBL] [Abstract] [Full Text] [Related]
13. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract] [Full Text] [Related]
14. Gene set enrichment analysis and ingenuity pathway analysis of metastatic clear cell renal cell carcinoma cell line.
Khan MI; Dębski KJ; Dabrowski M; Czarnecka AM; Szczylik C
Am J Physiol Renal Physiol; 2016 Aug; 311(2):F424-36. PubMed ID: 27279483
[TBL] [Abstract] [Full Text] [Related]
15. A Randomized, Open-Label Phase 2 Study of the cxcr4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Hainsworth JD; Reeves JA; Mace JR; Crane EJ; Hamid O; Stille JR; Flynt A; Roberson S; Polzer J; Arrowsmith ER
Target Oncol; 2016 Oct; 11(5):643-653. PubMed ID: 27154357
[TBL] [Abstract] [Full Text] [Related]
16. Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells.
Khan MI; Czarnecka AM; Helbrecht I; Bartnik E; Lian F; Szczylik C
Stem Cell Res Ther; 2015 Sep; 6(1):178. PubMed ID: 26377541
[TBL] [Abstract] [Full Text] [Related]
17. Stem cells increase in numbers in perinecrotic areas in human renal cancer.
Varna M; Gapihan G; Feugeas JP; Ratajczak P; Tan S; Ferreira I; Leboeuf C; Setterblad N; Duval A; Verine J; Germain S; Mongiat-Artus P; Janin A; Bousquet G
Clin Cancer Res; 2015 Feb; 21(4):916-24. PubMed ID: 25501128
[TBL] [Abstract] [Full Text] [Related]
18. cxcr4 and CXCR7 transduce through mTOR in human renal cancer cells.
Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
[TBL] [Abstract] [Full Text] [Related]
19. The role of inflammation in kidney cancer.
de Vivar Chevez AR; Finke J; Bukowski R
Adv Exp Med Biol; 2014; 816():197-234. PubMed ID: 24818725
[TBL] [Abstract] [Full Text] [Related]
20. BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.
Jiang J; Thyagarajan-Sahu A; Loganathan J; Eliaz I; Terry C; Sandusky GE; Sliva D
Oncol Rep; 2012 Oct; 28(4):1139-45. PubMed ID: 22842551
[TBL] [Abstract] [Full Text] [Related]
[Next]
